Houston's large immunocompromised population — including HIV-positive individuals on antiretrovirals, transplant recipients at the Texas Medical Center, and oncology patients at MD Anderson — represents a significant cohort at elevated risk from COVID-19. Molnulee provides Houston hospitals and pharmacies with affordable generic Molnupiravir for these high-risk patient groups.
The Texas Medical Center — the world's largest medical complex — creates substantial institutional demand for COVID antiviral treatment access. Wholesale supply of Molnulee at competitive pricing with full WHO-GMP documentation supports Houston's hospital pharmacy procurement teams.
The Texas Medical Center — the world's largest medical complex — creates substantial institutional demand for COVID antiviral treatment access. Wholesale supply of Molnulee at competitive pricing with full WHO-GMP documentation supports Houston's hospital pharmacy procurement teams.
Who should take Molnulee and who should avoid it?Molnupiravir (Molnulee) is indicated for high-risk adults with COVID-19 who do not require hospitalisation — specifically those with at least one risk factor for severe disease (age over 60, obesity, diabetes, heart disease, immunocompromised status, etc.). It should be started within 5 days of symptom onset. Who should avoid it: pregnant women (due to theoretical fetal risk from its mutagenic mechanism); women who are breastfeeding; children and adolescents (not studied in paediatric populations); and patients who are already hospitalised or require supplemental oxygen (where it hasn't demonstrated clear benefit). Always discuss suitability with a physician before taking.
